Haplogen

Haplogen develops therapeutics to treat infectious diseases, primarily virus infections.

Haplogen’s most advanced program is in the area of rhinovirus-mediated exacerbations of obstructive lung diseases, COPD and asthma.

Haplogen Bioscience, a spin-off, develops antiviral therapies against Zika and Dengue virus infections.